Mylan Settles With Sunovion Over Lunesta Generic Plans

Law360, New York (April 2, 2013, 7:47 PM EDT) -- Generic drugmaker Mylan Inc. on Tuesday agreed to a settlement with Sunovion Pharmaceuticals Inc., ending claims that one of its units’ planned generic version of sleep aid Lunesta infringed several Sunovion patents, according to an agreement filed in New Jersey federal court.

Under the terms of the deal, which was approved by U.S. District Judge Susan D. Wigenton, the companies have agreed to drop all claims and counterclaims over whether Mylan unit Alphapharm Pty. Ltd. infringed on Sunovion’s four Lunesta patents — U.S. Patent Numbers 6,319,926;...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.